PATENTS

IN THE UNITED STATES PATENT AND TRADMARK OFFICE

Applicants: Sheng C. Lou, et al.

Serial No.: 09/731,126

Filed: December 6, 2000

Patent No.: 6818392

Issued: November 16, 2004

Title: Monoclonal Antibodies to Human Immunodeficiency Virus and Uses Thereof

Case No.: 6755US01

Group Art No.: 1648

Examiner: Jeffrey S. Parkin

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as

first class mail in an envelope addressed to the:

Certificate of Correction Branch Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

Date of Deposit:

aShae Y Lewis

1/5/04

REQUEST FOR CERTIFICATE OF CORRECTION

Certificate of Correction Branch Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

Upon review of the final printed copies of the above-identified patent and comparison with the application file, Applicants have identified errors in the patent as printed. Accordingly, Applicants request that a Certificate of Correction be issued pursuant to 35 U.S.C. 254 for this patent as set forth on the attached Form PTO 1050, identifying errors by column and line from the patent. Since the errors appear to be due to the fault of the Patent and Trademark Office, Applicants believe no fee is due.

Respectfully submitted, Sheng C. Lou, et al.

ABBOTT LABORATORIES

Customer Number 23492 Telephone: (847) 935-1729

Facsimile: (847) 938-2623

Chervl L. Becker

Registration No. 35, 441

Attorney for Applicants

Certifica JAN 1 7 ZUUG JAN 1 3 2006

of Correction

TITAL + # 2885



IN THE UNITED STATES PATENT AND TRADMARK OFFICE

pplicants: Sheng C. Lou, et al.

Serial No.: 09/731,126

Filed: December 6, 2000

Patent No.: 6818392

Issued: November 16, 2004

Title: Monoclonal Antibodies to Human Immunodeficiency Virus and Uses Thereof

Case No.: 6755US01

Group Art No.: 1648

Examiner: Jeffrey S. Parkin

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to the:

Certificate of Correction Branch Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Date of Deposit:

LaShae Y. Le

Date 15/06

TRANSMITTAL LETTER

Certificate of Correction Branch Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

Enclosed herewith for the patent application identified above entitled Monoclonal Antibodies to Human Immunodeficiency Virus and Uses Thereof are the following:

- 1. Request for Certificate of Correction;
- 2. Certificate of Correction (PTO 1050), in duplicate; and
- 3. Return Receipt Postcard

The Commissioner is herby authorized to charge any additional Filing Fees required under 37 CFR §1.16, as well as any patent application processing fees under 37 CFR §1.17 associated with this communication for which full payment had not been tendered, to Deposit Account No. 01-0025.

Respectfully submitted, Sheng C. Lou, et al.

ABBOTT LABORATORIES

Customer Number 23492 Telephone: (847) 935-1729

Facsimile: (847) 938-2623

Cheryl L. Beoker

Registration No. 35, 441 Attorney for Applicants

TON TY 2005

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

(Also Form PTO-1050)

UNITED STATES PATENT AND TRADEMARK OFFICE CERTIFICATE OF CORRECTION

CERTIFICATE OF CORRECTION			
PATENT NO. :6	818392		Page 1 of 1
APPLICATION NO.: 0			
	November 16, 2004	happened flow or specific	
INVENTOR(S) : S	sheng C Lou, et al.		
It is certified that an error appears or errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:			
Col. 34, after	r claim 7 add "claim 8"		
"The method of claim 7 wherein said antibody of said indicator reagent of step (a) is selected from the group consisting of 120A-270, 115B-151, 117-289, 103-350, 115B-303 and 108-394.			
Col. 34, after	r claim 8 add "claim 9"		
"The method of claim 7 wherein said at least one monoclonal antibody of step (a) is 120A-270 and said antibody of said indicator reagent of step (a) is 115B-151.			

MAILING ADDRESS OF SENDER (Please do not use customer number below): 6818392

Robert DeBerardine Abbott Laboratories Dept. 377 AP6A-1 100 Abbott Park Road Abbott Park, IL 60064

2

This collection of information is required by 37 CFR 1.322, 1.323, and 1.324. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1.0 hour to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Attention Certificate of Corrections Branch, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

(Also Form PTO-1050)

UNITED STATES PATENT AND TRADEMARK OFFICE CERTIFICATE OF CORRECTION

	Dana 1 of 1		
PATENT NO.	:6818392 Page <u>l</u> of <u>l</u>		
APPLICATION NO.: 09/731.126			
ISSUE DATE	November 16, 2004		
INVENTOR(S)	: Sheng C Lou, et al.		
It is certified that an error appears or errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:			
Col. 34, a	after claim 7 add "claim 8"		
"The method of claim 7 wherein said antibody of said indicator reagent of step (a) is selected from the group consisting of 120A-270, 115B-151, 117-289, 103-350, 115B-303 and 108-394.			
Col. 34,	after claim 8 add "claim 9"		
"The method of claim 7 wherein said at least one monoclonal antibody of step (a) is 120A-270 and said antibody of said indicator reagent of step (a) is 115B-151.			
-			

MAILING ADDRESS OF SENDER (Please do not use customer number below): 6818392

Robert DeBerardine Abbott Laboratories Dept. 377 AP6A-1 100 Abbott Park Road Abbott Park, IL 60064

2

This collection of information is required by 37 CFR 1.322, 1.323, and 1.324. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1.0 hour to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Attention Certificate of Corrections Branch, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.